Star Combo Financials
| S66 Stock | 0.15 0.01 7.14% |
Star | Select Account or Indicator |
Please note, the imprecision that can be found in Star Combo's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Star Combo Pharma. Check Star Combo's Beneish M Score to see the likelihood of Star Combo's management manipulating its earnings.
Star Combo Stock Summary
Star Combo competes with Charter Hall, Southern Cross, Retail Food, ARN Media, and Star Entertainment. Star Combo is entity of Australia. It is traded as Stock on AU exchange.Specialization | Consumer Defensive, Household & Personal Products |
| Instrument | Australia Stock View All |
| Exchange | Australian Securities Exchange |
| ISIN | AU0000004798 |
| Business Address | 171-177 Woodpark Road, |
| Sector | Personal Care Products |
| Industry | Consumer Staples |
| Benchmark | Dow Jones Industrial |
| Website | www.starcombo.com.au |
| Phone | 61 2 9756 6555 |
You should never invest in Star Combo without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Star Stock, because this is throwing your money away. Analyzing the key information contained in Star Combo's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Star Combo Key Financial Ratios
Star Combo's financial ratios allow both analysts and investors to convert raw data from Star Combo's financial statements into concise, actionable information that can be used to evaluate the performance of Star Combo over time and compare it to other companies across industries.| Revenue | 26.02 M | ||||
| Gross Profit | 4.82 M | ||||
| EBITDA | 2.79 M | ||||
| Net Income | 747.33 K | ||||
| Cash And Equivalents | 6.5 M |
Star Combo Key Balance Sheet Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Total Assets | 43.3M | 43.4M | 42.2M | 42.8M | 49.2M | 36.6M | |
| Other Current Liab | 1.3M | 1.5M | 1.7M | 1.9M | 2.2M | 1.5M | |
| Other Liab | 604.6K | 461.8K | 79.0K | 607.4K | 698.5K | 491.4K | |
| Net Tangible Assets | 35.3M | 33.7M | 34.7M | 32.4M | 37.3M | 24.3M | |
| Net Debt | (14.0M) | (6.3M) | (5.3M) | 1.9M | 2.1M | 2.3M | |
| Retained Earnings | (6.5M) | (7.1M) | (10.3M) | (10.1M) | (9.1M) | (8.6M) | |
| Accounts Payable | 2.1M | 2.3M | 2.4M | 2.8M | 3.2M | 2.3M | |
| Cash | 17.3M | 10.4M | 9.5M | 2.2M | 2.5M | 2.4M | |
| Other Assets | 1.5M | 896.9K | 922.5K | 709.7K | 816.1K | 857.2K | |
| Long Term Debt | 1.5M | 115.9K | 79.5K | 9.2K | 8.2K | 7.8K | |
| Net Receivables | 4.4M | 3.2M | 4.3M | 4.5M | 5.2M | 3.6M | |
| Long Term Debt Total | 4.9M | 3.1M | 4.0M | 4.0M | 4.6M | 2.4M | |
| Inventory | 4.5M | 5.4M | 4.2M | 6.3M | 7.3M | 4.7M | |
| Other Current Assets | 156.7K | 136.5K | 121.0K | 173.5K | 199.6K | 249.1K | |
| Total Liab | 7.1M | 8.0M | 9.0M | 9.3M | 10.7M | 7.4M | |
| Total Current Assets | 26.4M | 19.1M | 18.1M | 18.4M | 21.1M | 20.2M | |
| Short Term Debt | 174.6K | 169.9K | 163.8K | 156.6K | 140.9K | 233.4K | |
| Common Stock | 67.7M | 67.3M | 67.2M | 67.3M | 77.4M | 52.4M | |
| Net Invested Capital | 46.6M | 36.3M | 35.5M | 33.1M | 38.1M | 32.0M | |
| Net Working Capital | 30.7M | 22.9M | 15.1M | 13.8M | 15.8M | 18.0M | |
| Intangible Assets | 2.5M | 699.8K | 690.0K | 677.2K | 609.5K | 1.2M | |
| Capital Stock | 67.7M | 67.3M | 67.2M | 67.3M | 77.4M | 68.7M | |
| Cash And Equivalents | 20M | 12.1M | 6M | 6.5M | 5.9M | 7.3M |
Star Combo Key Income Statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Total Revenue | 26.7M | 22.9M | 24.7M | 26.0M | 29.9M | 20.2M | |
| Gross Profit | 4.6M | 5.6M | 7.2M | 5.4M | 6.3M | 4.8M | |
| Operating Income | (889.8K) | 549.2K | 1.1M | 723.4K | 651.1K | 683.6K | |
| Ebit | (7.2M) | (910.2K) | (3.3M) | 1.2M | 1.1M | 1.1M | |
| Ebitda | (6.4M) | (126.7K) | (2.5M) | 2.8M | 2.5M | 2.6M | |
| Cost Of Revenue | 22.1M | 17.3M | 17.5M | 20.6M | 23.7M | 15.5M | |
| Income Before Tax | (7.5M) | (1.1M) | (3.5M) | 1.0M | 901.0K | 946.0K | |
| Net Income | (7.9M) | (696.3K) | (4.0M) | 747.3K | 672.6K | 706.2K | |
| Income Tax Expense | 412.5K | (385.3K) | 548.0K | 253.7K | 228.4K | 239.8K | |
| Tax Provision | (557.7K) | 412.5K | (385.3K) | 548.0K | 493.2K | 517.9K | |
| Interest Expense | 235.7K | 171.5K | 186.9K | 196.1K | 225.6K | 165.3K | |
| Interest Income | 412.1K | 288.5K | 52.2K | 233.8K | 268.9K | 180.7K | |
| Net Interest Income | (393.9K) | (129.6K) | (119.2K) | (58.5K) | (52.6K) | (55.3K) |
Star Combo Key Cash Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Other Non Cash Items | 6.5M | 1.0M | 5.2M | (4.2K) | (4.8K) | (4.6K) | |
| Capital Expenditures | 7.3M | 7.3M | 2.7M | 1.4M | 1.7M | 2.9M | |
| Net Income | (7.9M) | (696.3K) | (4.0M) | 747.3K | 672.6K | 706.2K | |
| Change To Inventory | 877.0K | (869.6K) | 1.2M | (2.1M) | (1.9M) | (1.8M) | |
| Change In Cash | (9.3M) | (2.9M) | (1.4M) | (824.2K) | (741.8K) | (704.7K) | |
| Net Borrowings | 1.6M | (2.1M) | (169.1K) | 70.3K | 63.3K | 66.5K | |
| Depreciation | 832.4K | 783.5K | 740.4K | 1.0M | 1.2M | 1.3M | |
| End Period Cash Flow | 17.3M | 4.4M | 3.0M | 2.2M | 2.5M | 2.4M | |
| Change To Netincome | (900.2K) | 5.8M | 1.5M | 4.1M | 4.7M | 4.9M | |
| Free Cash Flow | (6.9M) | (7.2M) | (851.8K) | (1.8M) | (1.6M) | (1.7M) | |
| Investments | (3.6M) | (7.5M) | 4.1M | (3.2M) | (3.7M) | (3.9M) |
Star Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Star Combo's current stock value. Our valuation model uses many indicators to compare Star Combo value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Star Combo competition to find correlations between indicators driving Star Combo's intrinsic value. More Info.Star Combo Pharma is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers reporting about 0.61 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Star Combo Pharma is roughly 1.65 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Star Combo's earnings, one of the primary drivers of an investment's value.Star Combo Pharma Systematic Risk
Star Combo's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Star Combo volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Star Combo Pharma correlated with the market. If Beta is less than 0 Star Combo generally moves in the opposite direction as compared to the market. If Star Combo Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Star Combo Pharma is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Star Combo is generally in the same direction as the market. If Beta > 1 Star Combo moves generally in the same direction as, but more than the movement of the benchmark.
Star Combo Pharma Total Assets Over Time
Star Combo January 4, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Star Combo help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Star Combo Pharma. We use our internally-developed statistical techniques to arrive at the intrinsic value of Star Combo Pharma based on widely used predictive technical indicators. In general, we focus on analyzing Star Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Star Combo's daily price indicators and compare them against related drivers.
| Downside Deviation | 13.19 | |||
| Information Ratio | 0.0204 | |||
| Maximum Drawdown | 29.67 | |||
| Value At Risk | (12.50) | |||
| Potential Upside | 8.33 |
Additional Tools for Star Stock Analysis
When running Star Combo's price analysis, check to measure Star Combo's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Star Combo is operating at the current time. Most of Star Combo's value examination focuses on studying past and present price action to predict the probability of Star Combo's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Star Combo's price. Additionally, you may evaluate how the addition of Star Combo to your portfolios can decrease your overall portfolio volatility.